FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $692.42M | ||||
Company | Location |
Date | Amt. (M) |
Details |
| ||||
Aegera |
Montreal |
11/20/06 |
$21 |
The Series C round included a $14M equity financing and a $7M debt facility; VenGrowth Advanced Life Sciences Fund Inc. led the financing, which included GrowthWorks, Business Development Bank of Canada, Desjardins Venture Capital, Multiple Capital and Solidarity Fund |
Alba |
Baltimore |
11/27/06 |
$10 |
A $10M debt commitment was provided by a syndicate consisting of Atel Ventures Inc., Oxford Finance Corp. and SVB Silicon Valley Bank |
Alimera |
Atlanta |
11/27/06 |
$15.9 |
Alimera added $15.9M to the $31.8M raised in 2005 in the first part of its Series B financing; investors in both tranches included BA Venture Partners, Domain Associates, Intersouth Partners, Polaris Venture Partners and Venrock Associates |
AnaMar |
Goteborg, Sweden |
11/16/06 |
SEK50 ($7.1) |
The company's larget shareholder, Koncentra Holding AB, is providing the SEK50M investment; LinkMed AB, the second largest stockholder, has an option to invest SEK7.5M |
AmpliMed Corp. |
Tucson, Ariz. |
11/28/06 |
$8.5 |
AmpliMed raised $8.5M in the second tracnhe of a Series B financing, bringing the round to about $14.6M; the investment was led by Biotech Insight Ventures and other existing investors InvestBio Ventures, Valley Ventures and Solstice Capital |
Cara |
Tarrytown, N.Y. |
11/28/06 |
$19 |
The Series C financing included new investors MVM Life Science Partners and Alta Biopharma Partners, and existing investor Ascent Biomedical Ventures |
Cerenis |
Ann Arbor, Mich., and Toulouse, France |
1/13/06 |
$53.5 |
The Series B financing was led by TVM Capital, which was joined by OrbiMed and previous investors Sofinnova Partners, HealthCap, Alta Partners, EDF Ventures and NIF SMBC Ventures |
Chiasma Inc. |
Boston |
11/15/06 |
$44 |
The Series C financing was led by MPM Capital, with participation by ARCH Venture Partners and existing investors Ofer Hi-tech Group and F-2 Ventures |
Concert |
Lexington, Mass. |
11/30/06 |
$48.5 |
The Series B financing was led by new investor Flagship Ventures and included Brookside Capital Partners Fund LP and New Leaf Venture Partners, as well as existing investors Three Arch Partners, TVM Capital, Skyline Ventures, Greylock Partners and QVT Fund LP |
Elixir |
Cambridge, Mass. |
11/28/06 |
$46 |
The Series C round included $31M in equity and $15M in debt; the equity portion was led by MPM Capital and included existing investors ARCH Venture Partners and Oxford BioScience Partners, and new investors CDIB, JAFCO and YFY Bio- science; Hercules Technology Growth Capital Inc. provided the debt funding |
ERA Biotech |
Barcelona, Spain |
11/30/06 |
|1.4($1.9) |
Invertec, Reus Capital Riesgo, Talde Capial II and Uninvest each provided |0.3M in convertible loans to lead the seed funding round |
EyeGate |
Paris |
11/2/06 |
$10 |
The Series B financing round was co-led by Innoven Partenaires and Ventech |
Intradigm |
Palo Alto, Calif. |
11/21/06 |
$16 |
The Series A financing was co-led by Alta Partners and Frazier Healthcare Ventures, and included existing investors Emerging Technology Partners and Novartis' Ventures Fund, and new investors MediBic Alliance/Daiichi and Genentech Corp. |
Kalypsys Inc. |
San Diego |
11/29/06 |
$100 |
The $100M Series C financing round included an $89M investment by existing investor Tavistock Life Sciences; existing investors also participat- ing were Sprout Group, CMEA Ventures and KT Venture Group |
MedGenesis |
Victoria, British Columbia |
11/8/06 |
$3.2 |
Details on the equity financing were not disclosed |
Merrion |
Dublin, Ireland |
11/29/06 |
|8 (10.6) |
About |6M of the financing round was provided earlier in the year by existing investors; Goodbody Stockbrokers managed the deal |
Myconostica |
Manchester, UK |
11/27/06 |
£1 ($1.96) |
Amphon Innovations plc provided funding for the University of Manchester spinoff |
Neurotech |
Lincoln, R.I. |
11/16/06 |
$35 |
The Series B financing was led by Burrill and Co., with participation from Versant Ventures and SV Life Sciences; other new investors were Omega Fund, Nexus Medical Partners and Pound Capital, which joined existing investors Apax Partners France, Merlin Biosciences, Atlas Venture, Mayflower, Avida Group and Alpha Associates |
Orexigen |
San Diego |
11/22/06 |
$30 |
New investors MPM BioEquities and Wasatch Advisors joined existing investors in the Series C financing round |
Palau Pharma |
Barcelona, Spain |
11/1/06 |
|40($52.5) |
The company was spun out of Grupo Uriach's R&D unit; acquiring a minority stake in Palau in the intial funding were Invercartera, Caja Duero, the Cerqueda family and Najeti Capital |
PharmaKodex |
Chippenham, UK |
11/16/06 |
£7.1($13.6) |
The Series A financing round was co-led by Apposite Capital and SR One Ltd.; Unilever Ventures and Vectura Group plc also participated |
Renovar Inc. |
Madison, Wis. |
11/30/06 |
$1.22 |
Investing the second-round financing were NEW Capital Fund LP, Wisconsin Investment Partners and individuals, including the company's CEO |
Solstice |
Malvern, Pa. |
11/8/06 |
$85 |
The $85M included a Series B investment and a debt financing; Highland Capital Management LP led the Series B round, which included Series A investors Thomas, McNerney & Partners; Investor Growth Capital Inc.; Morgan Stanley Venture Partners; and Oxford Bioscience Partners |
TetraPhase |
Watertown, Mass. |
11/27/06 |
$25 |
Investors in the Series A financing included Mediphase Venture Partners, Fidelity Biosciences, Skyline Ventures, Flagship Ventures and CMEA Ventures |
Xanthus |
Cambridge, Mass. |
11/30/06 |
$25 |
The Series B financing was provided by existing investors Oxford Bioscience Partners, HealthCare Ventures, GeneChem, GIMV, Hambrecht & Quist Capital Management, Still River Fund, Neomed, Kestrel Ventures, CDP Capital, CDIB BioScience Ventures and Yasuda |
Xceleron Ltd. |
York, UK |
11/30/06 |
£2($3.94) |
Close Ventures provided £1.5M of the funding; the balance was provided by Foursome Investments along with company directors and management |
Yaupon |
Radnor, Pa. |
11/13/06 |
$4 |
The Series B financing was led by Osage Ventures and included the BioAdvance Greenhouse Fund, Ben Franklin Technology Partners and TDH Capital |
| ||||
Notes: | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
ND = Not disclosed. | ||||